FLT3-ITD阳性母细胞期慢性粒-单核细胞白血病患者中继发FLT3/A848P突变的鉴定及对舒尼替尼和索拉非尼的反应 - Suppr

Suppr

超能文献

Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.

作者信息

von Bubnoff N, Rummelt C, Menzel H, Sigl M, Peschel C, Duyster J

出版信息

Leukemia. 2010 Aug;24(8):1523-5. doi: 10.1038/leu.2010.122. Epub 2010 Jun 3.

DOI:10.1038/leu.2010.122

PMID:20520641

Abstract

摘要

相似文献

Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.FLT3-ITD阳性母细胞期慢性粒-单核细胞白血病患者中继发FLT3/A848P突变的鉴定及对舒尼替尼和索拉非尼的反应

Leukemia. 2010 Aug;24(8):1523-5. doi: 10.1038/leu.2010.122. Epub 2010 Jun 3.

Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.不同的激活型和耐药型FLT3-ITD突变对索拉非尼和舒尼替尼的敏感性各异。

Exp Hematol. 2007 Oct;35(10):1522-6. doi: 10.1016/j.exphem.2007.07.008.

Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.伴有 DNMT3A 和 FLT3-ITD 双突变的慢性粒单核细胞白血病患者接受地西他滨和索拉非尼治疗。

Cancer Biol Ther. 2017 Nov 2;18(11):843-849. doi: 10.1080/15384047.2017.1281491. Epub 2017 Jan 19.

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.索拉非尼和舒尼替尼序贯治疗 FLT3-ITD 阳性急性髓系白血病时出现多克隆 FLT3 酪氨酸激酶结构域突变。

Clin Cancer Res. 2013 Oct 15;19(20):5758-68. doi: 10.1158/1078-0432.CCR-13-1323. Epub 2013 Aug 22.

Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.伴嗜酸性粒细胞增多的 ETV6-FLT3 阳性髓系/淋系肿瘤对 FMS 样酪氨酸激酶 3 抑制剂的反应。

Blood. 2011 Aug 25;118(8):2239-42. doi: 10.1182/blood-2011-03-343426. Epub 2011 Jun 24.

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.索拉非尼在FLT3-ITD阳性急性髓系白血病中的同情用药：异基因造血干细胞移植前后的持续缓解

Blood. 2009 Jun 25;113(26):6567-71. doi: 10.1182/blood-2009-03-208298. Epub 2009 Apr 23.

The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.继发性FLT3-ITD F691L突变可诱导FLT3-ITD阳性急性髓系白血病（AML）对AC220产生耐药，但对PKC412和舒尼替尼仍保留体外敏感性。

Leukemia. 2013 Jun;27(6):1416-8. doi: 10.1038/leu.2013.14. Epub 2013 Jan 16.

[Sorafenib in combination with chemotherapy in the induction therapy for FLT3-ITD positive acute monocytic leukemia: a case report and literature review].

Zhonghua Xue Ye Xue Za Zhi. 2011 Jan;32(1):8-11.

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.FMS样酪氨酸激酶3-内部串联重复酪氨酸激酶抑制剂在体外显示出不重叠的耐药突变谱。

Cancer Res. 2009 Apr 1;69(7):3032-41. doi: 10.1158/0008-5472.CAN-08-2923. Epub 2009 Mar 24.

Sorafenib and sunitinib.索拉非尼和舒尼替尼。

Oncologist. 2009 Aug;14(8):800-5. doi: 10.1634/theoncologist.2009-0088. Epub 2009 Aug 1.

引用本文的文献

Targeting rapid TKI-induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia.靶向TKI诱导的AXL快速上调可克服适应性ERK重新激活，并在FLT3/ITD急性髓系白血病中发挥抗白血病作用。

Mol Oncol. 2025 May;19(5):1386-1403. doi: 10.1002/1878-0261.13749. Epub 2024 Oct 12.

Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure.克服耐药性：FLT3抑制剂的过去、现在、未来与治愈挑战

Cancers (Basel). 2022 Sep 2;14(17):4315. doi: 10.3390/cancers14174315.

FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation.FLT3 抑制剂治疗异基因造血细胞移植后预防和治疗复发。

Int J Hematol. 2022 Sep;116(3):341-350. doi: 10.1007/s12185-022-03352-6. Epub 2022 Apr 23.

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.急性髓系白血病中 FLT3 抑制剂耐药的分子机制：持续存在的挑战和未来的治疗方法。

Cells. 2020 Nov 17;9(11):2493. doi: 10.3390/cells9112493.

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.吉特替尼是一种临床活性的 FLT3 抑制剂，对 FLT3 激酶结构域突变具有广泛的活性。

Blood Adv. 2020 Feb 11;4(3):514-524. doi: 10.1182/bloodadvances.2019000919.

CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.CCL5 通过介导靶激酶非依赖性机制导致 FLT3-ITD 阳性 AML 对 FLT3 抑制剂产生耐药。

Mol Oncol. 2020 Apr;14(4):779-794. doi: 10.1002/1878-0261.12640. Epub 2020 Feb 13.

Cancer Biol Ther. 2017 Nov 2;18(11):843-849. doi: 10.1080/15384047.2017.1281491. Epub 2017 Jan 19.

The Biology and Targeting of FLT3 in Pediatric Leukemia.FLT3 在儿科白血病中的生物学和靶向治疗。

Front Oncol. 2014 Sep 23;4:263. doi: 10.3389/fonc.2014.00263. eCollection 2014.

Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutations.靶向癌蛋白稳定性可克服由FLT3激酶结构域突变引起的耐药性。

PLoS One. 2014 May 21;9(5):e97116. doi: 10.1371/journal.pone.0097116. eCollection 2014.

FLT3 inhibitors in AML: are we there yet?急性髓系白血病中的FLT3抑制剂：我们成功了吗？

Curr Hematol Malig Rep. 2014 Jun;9(2):174-85. doi: 10.1007/s11899-014-0203-8.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验